# Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

> **NCT00465673** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT00465673
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2009-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00465673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00465673, "Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00465673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*